Veracyte Stock Price, News & Analysis

Veracyte (Nasdaq: VCYT) announced that Bonnie Anderson, CEO and Chairman, will participate in a fireside chat during the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 2:15 p.m. ET. The live audio webcast can be accessed via Veracyte's website, and a replay will be available for 90 days post-event. Veracyte is known for its genomic diagnostics which aid in cancer diagnosis and treatment, offering tests for lung, prostate, breast, thyroid, and bladder cancers.

Veracyte, Inc. (Nasdaq: VCYT) has appointed Muna Bhanji, R.Ph., a seasoned healthcare executive, to its board of directors. With over 30 years in the biopharmaceutical field, Bhanji's expertise includes commercialization and market access strategies across global markets. CEO Bonnie Anderson expressed confidence in Bhanji's ability to support Veracyte's expansion, particularly with the upcoming international launch of the Envisia Genomic Classifier aimed at enhancing diagnostic capabilities for lung disease.

Veracyte has completed its acquisition of Decipher Biosciences for $600 million, enhancing its position in genomic diagnostics and expanding to address 7 of the 10 most common cancers in the U.S. This strategic move aims to accelerate revenue growth and improve patient outcomes by leveraging Decipher's expertise in urologic cancers alongside Veracyte's advanced testing platform. Dr. Tina Nova, former CEO of Decipher, will lead urologic cancers operations at Veracyte.

Veracyte (Nasdaq: VCYT) applauded the U.S. Preventive Services Task Force (USPSTF) for its revised lung cancer screening recommendations, lowering the screening age from 55 to 50 and reducing smoking history criteria. This change is expected to increase eligibility for low-dose CT scans to nearly 15 million Americans. The company emphasizes the importance of early detection in saving lives and is developing innovative tests to enhance the diagnosis and management of lung cancer. The Percepta® Genomic Sequencing Classifier and a noninvasive nasal swab test are set to launch in late 2021.

Veracyte, a global genomic diagnostics company (Nasdaq: VCYT), announced that its CEO, Bonnie Anderson, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 3:40 p.m. Eastern Time. A live audio webcast will be available on Veracyte’s website, with a replay accessible for 90 days post-event. Veracyte focuses on improving patient care through genomic tests for diseases like cancer, minimizing the need for invasive procedures and expediting appropriate treatment.

Veracyte, Inc. (Nasdaq: VCYT) reported Q4 2020 revenue of $34.5 million, a 16% increase year-over-year, driven by a rebound in genomic testing volumes. However, total revenue for the full year decreased by 2% to $117.5 million. The company expects to close its $600 million acquisition of Decipher Biosciences by April 1, 2021, aiming for combined revenue of $190 million to $200 million in 2021, a 65% growth outlook. Operating expenses rose 13% in Q4, contributing to a net loss of $8.0 million for the quarter.

Veracyte, Inc. (Nasdaq: VCYT) has announced that Bonnie Anderson, chairman and CEO, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18 at 1:30 p.m. Eastern Time. Investors can access the live audio webcast via Veracyte’s website, with a replay available for 90 days post-presentation. Veracyte is a global genomic diagnostics company focused on enhancing patient care through genomic testing for cancer and other diseases, aiming to facilitate quicker diagnosis and treatment.

Veracyte, Inc (Nasdaq: VCYT) will release its full financial results for Q4 and the full year 2020 post-market on February 17. A conference call will follow at 4:30 p.m. ET, where management will discuss financial results and provide a business update. Participants can join via the toll-free U.S./Canada dial-in at (855) 541-0980 or international number (970) 315-0440, using Conference I.D. 7487201. Veracyte leverages genomic diagnostics to enhance patient care and is expanding its test offerings in cancer and other diseases.

Veracyte, Inc. (Nasdaq: VCYT) has completed its public offering of 8,547,297 shares of common stock at a price of $74.00 per share. The offering raised approximately $593.8 million in net proceeds after accounting for underwriting discounts and expenses. This included 1,114,864 shares sold through the underwriters’ full exercise of their option to purchase additional shares. Goldman Sachs & Co. and SVB Leerink served as joint lead book-running managers, with several other firms as co-managers. The offering was conducted under a prior effective shelf registration.